secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001140361-23-058152
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis licenses donidalorsen European rights to Otsuka; $65M upfront, tiered royalties
--------------------------------------------------------------------------------

- Otsuka receives exclusive European commercialization rights to donidalorsen (HAE prophylactic).
- Ionis gets $65M upfront plus undisclosed regulatory/sales milestones.
- Ionis eligible for tiered royalties of 20-30% on European net sales.
- Ionis retains U.S. commercialization rights; plans to launch independently if approved.
- Phase 3 donidalorsen data expected H1 2024; Phase 2 OLE showed 96% attack rate reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036123058152/0001140361-23-058152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036123058152/ef20016866_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-058152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer